Khalaf Marwa M, Hassan Samar M, Sayed Ahmed M, Abo-Youssef Amira M
Pharmacology and Toxicology Department, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt.
Pharmacology and Toxicology Department, Faculty of Pharmacy, Fayoum University, Fayoum, Egypt.
Int Immunopharmacol. 2022 Jan;102:108382. doi: 10.1016/j.intimp.2021.108382. Epub 2021 Nov 28.
Nephrotoxicity is an indication for the damage of kidney-specific detoxification and excretion mechanisms by exogenous or endogenous toxicants. Exposure to vancomycin predominantly results in renal damage and losing the control of body homeostasis. Vancomycin-treated rats (200 mg/kg/once daily, for seven consecutive days, i.p.) revealed significant increase in serum pivotal kidney function, oxidative stress, and inflammatory biomarkers. Histologically, vancomycin showed diffuse acute tubular necrosis, denudation of epithelium and infiltration of inflammatory cells in the lining tubular epithelium in cortical portion. In the existing study, the conservative consequences of scopoletin against vancomycin nephrotoxicity was investigated centering on its capacity to alleviate oxidative strain and inflammation through streamlining nuclear factor (erythroid-derived-2) like 2 (Nrf2)/heme oxygenase-1 (HO-1) signaling and prohibiting the nuclear factor kappa B (NF-κB)/mitogen-activated protein kinase (p38 MAPK) pathway. With respect to vancomycin group, scopoletin pretreatment (50 mg/kg/once daily, i.p.) efficiently reduced kidney function, oxidative stress biomarkers and inflammatory mediators. Moreover, histological and immunohistochemical examination of scopoletin-treated group showed remarkable improvement in histological structure and reduced vancomycin-induced renal expression of iNOS, NF-κB and p38 MAPK. In addition, scopoletin downregulated (Kelch Like ECH Associated Protein1) Keap1, P38MAPK and NF-κB expression levels while upregulated renal expression levels of regulatory protein (IκBα), Nrf2 and HO-1. Furthermore, molecular docking and network approach were constructed to study the prospect interaction between scopoletin and the targeted proteins that streamline oxidative stress and inflammatory pathways. The present investigations elucidated that scopoletin co-treatment with vancomycin may be a rational curative protocol for mitigation of vancomycin-induced renal intoxication.
肾毒性是外源性或内源性毒物对肾脏特异性解毒和排泄机制造成损害的一种表现。接触万古霉素主要会导致肾脏损伤并失去对体内稳态的控制。用万古霉素治疗的大鼠(200毫克/千克/每日一次,连续7天,腹腔注射)显示血清关键肾功能、氧化应激和炎症生物标志物显著增加。组织学上,万古霉素表现为弥漫性急性肾小管坏死、上皮剥脱以及皮质部肾小管上皮内衬炎症细胞浸润。在现有研究中,以东莨菪亭减轻氧化应激和炎症的能力为中心,通过简化核因子(红细胞衍生-2)样2(Nrf2)/血红素加氧酶-1(HO-1)信号传导并抑制核因子κB(NF-κB)/丝裂原活化蛋白激酶(p38 MAPK)途径,研究了其对万古霉素肾毒性的保守作用。与万古霉素组相比,东莨菪亭预处理(50毫克/千克/每日一次,腹腔注射)有效降低了肾功能、氧化应激生物标志物和炎症介质。此外,对东莨菪亭治疗组的组织学和免疫组织化学检查显示组织结构有显著改善,万古霉素诱导的肾组织中诱导型一氧化氮合酶(iNOS)、NF-κB和p38 MAPK的表达降低。此外,东莨菪亭下调了( Kelch样ECH相关蛋白1)Keap1、P38MAPK和NF-κB的表达水平,同时上调了调节蛋白(IκBα)、Nrf2和HO-1的肾表达水平。此外,构建了分子对接和网络方法来研究东莨菪亭与简化氧化应激和炎症途径的靶向蛋白之间的潜在相互作用。目前的研究表明,东莨菪亭与万古霉素联合治疗可能是减轻万古霉素诱导的肾中毒的合理治疗方案。